Narayana Hrudayalaya Ltd.
NSE: NHNarayana Hrudayalaya Ltd.: A 30-second snapshot
Narayana Hrudayalaya (NH) is a hospital network operator trading at ₹1,841, with a trailing PE of 48.1 and a forward PE of 32.3, against a sector that ranges from 26.5x to 72.5x. The stock is 3.96% higher over 12 months and sits 22.1% below its 52-week high, currently above both the 50-DMA (₹1,746) and 200-DMA (₹1,811). An NCLT scheme of arrangement with NH Integrated Care, filed in May 2026, adds a corporate restructuring variable to the near-term picture.
P/E
48.1
Forward P/E
32.3
ROE
—
Debt / Equity
57.61
Profit Margin
+11.5%
Div. Yield
+0.2%
5Y ROE > 15%
4/5
5Y FCF > 0
3/5
Quality
53/100
News
5 headlines · 0 positive · 0 negative
Narayana Hrudayalaya Advances NCLT Scheme of Arrangement With NH Integrated Care - TipRanks
TipRanks
NH Guwahati offers kidney transplant programme for benefit of Northeast patients - The News Mill
The News Mill
Top stocks to buy today: Stock recommendations for May 13, 2026 - check list - The Times of India
The Times of India
Trade Spotlight: How should you trade Narayana Hrudayalaya, HDFC Life, Apollo Hospitals, Eternal, Laurus Labs, Max Healthcare, and others on May 12? - Moneycontrol.com
Moneycontrol.com
Narayana Health: Heart At The Right Place - BusinessLine
BusinessLine
Recent context
- ·Narayana Hrudayalaya filed an NCLT scheme of arrangement with NH Integrated Care (announced May 2, 2026), introducing a structural corporate reorganization whose financial terms and timeline are not yet fully disclosed.
- ·NH Guwahati launched a kidney transplant programme to extend services to Northeast India patients (May 16, 2026), consistent with the company's stated geographic expansion strategy.
- ·NH appeared alongside Apollo Hospitals and Max Healthcare in trade-focus coverage (Moneycontrol, May 12, 2026), reflecting ongoing institutional attention to the hospital sector without stock-specific directional commentary.
Strengths
- +ROE exceeded 15% in 4 of the tracked years, suggesting periods of meaningful capital efficiency in the hospital business.
- +Forward PE of 32.3 represents a 33% compression from the trailing PE of 48.1, reflecting analyst expectations of earnings recovery relative to the current price.
- +Five-year revenue growth of 57.4% demonstrates sustained capacity and patient-volume expansion across its hospital network.
- +Consistency score of 72 (out of 100) signals that key financial metrics have been reasonably stable, even if individual indicators like earnings have retreated.
Weaknesses
- −5-year earnings contracted 34.3% while revenue expanded 57.4%, indicating that cost escalation or capital structure has absorbed the scale-up without translating to profit growth.
- −Debt-to-equity of 57.6 with a rising debt trend and FCF-positive in only 3 of tracked years narrows the financial buffer for reinvestment or adverse operating conditions.
- −Quality score of 26 is the lowest in the peer set shown — Max Healthcare (54), Apollo Hospitals (42), and Sun Pharma (50) all rank above NH on composite quality metrics.
- −Dividend yield of 0.24% is minimal for a company with a PE above 48, offering little income offset to shareholders during periods of muted price performance.
Open questions
- ?Does the 5-year earnings contraction of 34.3% reflect one-time capacity investment costs that are now tapering, or is it indicative of a structural margin compression in the hospital business?
- ?What are the disclosed terms of the NCLT scheme of arrangement with NH Integrated Care, and how might a merger or restructuring affect the consolidated debt load and earnings base?
- ?How does NH's D/E of 57.6 compare to its own historical range, and at what debt level has the company historically shown FCF turning consistently positive?
- ?Given that the forward PE of 32.3 implies a significant earnings step-up, what revenue or margin assumptions underpin that estimate and how sensitive are they to occupancy rates and ARPU trends?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| NH | Narayana Hrudayalaya Ltd.You're viewing | 48.1 | — | 26 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.5 | +11.8% | 17 |
Technical state
Current price
₹1,841.10
SMA 50
₹1,746.58
SMA 200
₹1,810.69
RSI (14)
56.5 (neutral)
From 52w high
-22.1%
1Y return
+4.0%
3M return
-1.3%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumDebt-to-equity of 57.6 is elevated for a hospital operator with a rising debt trend; FCF-positive in only 3 of the last tracked years, limiting the buffer to service growing obligations.
- medium5-year earnings contracted 34.3% against 5-year revenue growth of 57.4%, indicating cost or capital-structure absorption has prevented top-line scale from reaching the bottom line; net profit margin is 11.5%.
- lowQuality score of 26 ranks 5th of 6 peers in the sector comparison set; Max Healthcare (54) and Apollo Hospitals (42) score materially higher, reflecting broader operational and return metrics.
- lowStock is 22.1% below its 52-week high; 1-year price gain of 3.96% and 3-month change of -1.26% indicate muted price momentum relative to the drawdown.
- lowNews volume is sparse at 5 articles, all neutral; low sample size limits the reliability of sentiment signals.
Cross-section contradictions
- Revenue grew 57.4% over 5 years while earnings contracted 34.3% over the same period — costs or capital structure have absorbed the top-line expansion without generating commensurate profit growth.
- Stock trades above both its 50-DMA (₹1,746) and 200-DMA (₹1,810) after a 22% drawdown from the 52-week high, a partial technical recovery that lacks a visible fundamental catalyst in current news flow.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days